HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: A multicenter study of the GINECO group

Annals of Oncology

Volumn 15, Issue 1, 2004, Pages 104-112

  Camilleri Broët, Sophie ^a   Hardy Bessard, A C ^a   Le Tourneau, A ^a   Paraiso, D ^a   Levrel, O ^a   Leduc, B ^b   Bain, S ^a   Orfeuvre, H ^c   Audouin, J ^a   Pujade Lauraine, E ^a  

^a HÔTEL DIEU   (France)

^b Ctr Hospitalier Brive La Gaillarde   (France)

^c Hopital Fleyriat   (France)

Author keywords

HER 2; Ovarian cancer; Prognosis

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; KI 67 ANTIGEN; PARAFFIN; PLATINUM DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 9144229428     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh021     Document Type: Article

References (33)

1. Clark TG, Stewart ME, Altman DG et al. A prognostic model for ovarian cancer. Br J Cancer 2001; 85: 944-952.
2. Bakhshi A, Jensen JP, Goldman P et al. Cloning the chromosomal breakpoint of t(14; 18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on chromosome 18. Cell 1985; 41: 899-906.
3. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1987; 244: 707-712.
4. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of HER-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356.
5. Vacher-Lavenu MC, Le Tourneau A, Duvillard et al. Pathological classification and grading of primary ovarian carcinoma: experience of the ARTAC ovarian study group. Bull Cancer 1993; 80: 135-141.
6. Couturier J, Vincent-Salomon A, Nicolas A et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000; 13: 1238-1243.
7. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
8. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-202.
9. Guastalla JP, Leduc B, Guichard F et al. Cyclophosphamide dose intensification with filgrastim support in first line CEP regimen in advanced cancer (AOC): a GINECO phase III study. Proc Am Soc Clin Oncol 2001; 2: 205a (Abstr 817).
10. Anttila M, Kosma VM, Ji H et al. Clinical significance of alpha-catenin, collagen TV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol 1998; 16: 2591-2600.
11. Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of BCL-2 in ovarian tumours. Br J Cancer 1995; 72: 1324-1329.
12. Herod JJ, Eliopoulos AG, Warwick J et al. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996; 56: 2178-2184.
13. Mano Y, Kikuchi Y, Yamamoto K et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 1999; 35: 1214-1219.
14. Marx D, Binder C, Meden H et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 1997; 17: 2233-2240.
15. Silvestrini R, Daidone MG, Veneroni S et al. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 1998; 82: 159-167.
16. Chan WY, Cheung KK, Schorge JO et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000; 156: 409-417.
17. Tai YT, Lee S, Niloff E et al. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998; 16: 2583-2590.
18. Marone M, Scambia G, Mozzetti S et al. Bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin Cancer Res 1998; 4: 517-524.
19. Ben-Hur H, Gurevich P, Huszar M et al. Apoptosis and apoptosis-related proteins in the epithelium of human ovarian tumors: immunohistochemical and morphometric studies. Eur J Gynaecol Oncol 1999; 20: 249-253.
20. Wehrli BM, Krajewski S, Gascoyne RD et al. Inummohistochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors. Int J Gynecol Pathol 1998; 17: 255-260.
21. Van der Zee AG, Hollema H, Suurmeijer AJ et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-78.
22. Ross JS, Yang F, Kallakury BV et al. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol 1999; 111: 311-316.
23. Medl M, Sevelda P, Czerwenka K et al. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol Oncol 1995; 59: 321-326.
24. Singeleton TP, Perrone T, Oakley G et al. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparaison with histologic type, grade and stage. Cancer 1994; 73: 1460-1465.
25. Goff BA, Ries JA, Els LP et al. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol 1998; 70: 378-385.
26. Nijman HW, Kenemans P, Poort-Keesom RJ et al. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999; 83: 201-206.
27. Meden H, Marx D, Roegglen T et al. Overexpression of the oncogene cerbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 1998; 17: 61-65.
28. Fajac A, Benard J, Lhomme C et al. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer 1995; 64: 146-151.
29. Tanner B, Kreutz E, Weikel W et al. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol Oncol 1996; 62: 268-277.
30. Felip E, Del Campo JM, Rubio D et al. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 1995; 75: 2147-2152.
31. Ferrandina G, Ranelletti FO, Lauriola L et al. Cyclooxygenase-2 (COX2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 2002; 85: 305-310.
32. Hengstler JG, Lange J, Kett A et al. Contribution of c-erbB-2 and topoisomerase II alpha to chemoresistance in ovarian cancer. Cancer Res 1999; 59: 3206-3214.
33. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000; 11: 647-663.